Pexidartinib

Pexidartinib
Clinical data
Routes of
administration		 By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C20H15ClF3N5
Molar mass 417.82 g·mol−1
3D model (JSmol)


Pexidartinib (PLX-3397) is a CSF1R inhibitor drug in development by Plexxikon[1][2] for the treatment of tenosynovial giant cell tumors.[3]

It is in a phase 3 clinical trial for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS).[4]

References

  1. ↑ Adis Insight drug profile: Pexidartinib
  2. ↑ Microglial Magic: Drug Wipes Them Out, New Set Appears (PLX3397)
  3. ↑ "FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor". October 30, 2015.
  4. ↑ Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) (ENLIVEN)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.